Funding announcement
Company
GSK
Funding history
Investors
Every investor coverage indicates participated in a round GSK raised.
What GSK bought
Companies GSK acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
| Name | Role | Sources |
|---|---|---|
| Dr Roberto Solari | Head of Respiratory Research (former) | Brandon BioCatalyst, Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Coverage
Stories naming GSK. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Grant
$18.9m
ENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.
A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.
Funding announcement
Professor got nothing from the $2.8b sale of his molecule, and that's okay
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Fund close
$30m
Andrew Wilks in Weekend Australian
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
Fund close
$20m
Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Also Forbes Australia
2 deals
Andrew Forrest backs Sydney biotech startup in $26 million raise
Sydney diagnostics developer SpeeDx banked $26 million for American expansion, with $5 million from Andrew Forrest's new fund Tenmile and follow-on support from Platinum and Northpond.
Also SmartCompany
Seed
$8.2m
Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
News
Meet the Aussie entrepreneur letting you diagnose the flu through your smartphone
Profile of Ellume, a Queensland diagnostics startup whose founder Dr Sean Parsons describes smartphone flu self-testing, partnerships with GSK and QIAGEN, and a planned ASX float within a year.